Bristol-Myers clears another hurdle in Merck lung cancer showdown — but big challenges remain

Bristol-Myers Squibb $BMY has had an awfully hard time getting analysts to like the promising data they’ve published on their Opdivo/Yervoy combo for frontline lung cancer.